Pharmaceutical compositions
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Oct 13, 2006
filing date -
Aug 28, 2002
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3.beta.-hydroxy-17.beta.-aminoandrost-5-ene, 3.beta.-hydroxy-16.alpha.-fluoro-17.beta.-aminoandrost-5-ene, 3.alpha.-hydroxy-16.alpha.-fluoro-17.beta.-aminoandrost-5-ene, 3.beta.-hydroxy-16.beta.-fluoro-17.beta.-aminoandrost-5-ene, 1.alpha.,3.beta.-dihydroxy-4.alpha.-fluoroandrost-5-ene-17-one, 1.alpha.,3.beta.,17.beta.-trihydroxy-4.alpha.-fluoroandrost-5-ene, 1.beta.,3.beta.-dihydroxy-6.alpha.-bromoandrost-5-ene, 1.alpha.-fluoro-3.beta.,12.alpha.-dihydroxyandrost-5-ene-17-one, 1.alpha.-fluoro-3.beta.,4.alpha.-dihydroxyandrost-5-ene and 4.alpha.-fluoro-3.beta.,6.alpha.,17.beta.-trihydroxyandrostane.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully